Overview

Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The aim of part 1 of this study is to determine the optimal biological dose (OBD) and maximum tolerated dose (MTD) for WX-554 and the recommended dose/dose schedules for the chronic treatment in part 2. The aim of part 2 is to further determine the safety and tolerability of chronic treatment with WX-554.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Heidelberg Pharma AG
Wilex